The Centre for Respiratory Research at McGill University and the Research Institute of the McGill University Health Centre
Category Archives: Chronic Airways Disease
Chronic Airways Disease Theme: Chronic airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchopulmonary dysplasia share common features of chronic airflow obstruction and structural changes of the airways. These disorders are associated with an underlying inflammatory process that is driven by genetic susceptibility as well as environmental factors such as allergens and cigarette smoke. The main research questions being investigated focus on elucidating the basic mechanisms that lead to the development of chronic airways disease. Studies are also attempting to identify and characterize the clinical heterogeneity of these diseases in order to better personalize prognostic, diagnostic and therapeutic tools.
Major scientific objectives of the chronic airways diseases theme include: (1) Elucidate pathogenetic mechanisms and develop novel therapeutics for allergic inflammation & airway hyperresponsiveness. (2) Understand the cellular and molecular basis for irritant (including air pollution & cigarette smoke) -induced lung disease, and its relevance to COPD and the Asthma-COPD Overlap Syndrome (ACOS). (3) Ascertain the biological basis for different asthma phenotypes, particularly severe asthma that is resistant to usual therapies.
View posts, news, and publications related to this research theme below.
Dr. Carolyn Baglole was featured in the July 2019 CCIC Newsletter. Her research was profiled in their monthly research highlights. Read the newsletter excerpt below.
Dr. Baglole received her BSc and MSc from the University of Prince Edward Island, and completed her PhD at the University of Calgary. She then did postdoctoral work in the fields of lung biology/toxicology in the Department of Environment Medicine at the University of Rochester (Rochester NY) before returning to Canada at McGill University.
Dr. Baglole’s translational research program seeks to identify novel cellular and molecular pathways that regulate the pathogenesis of chronic lung diseases. Her main research focus is to understand how these environmental exposures contribute to pathogenic mechanisms such as chronic inflammation and cell death (apoptosis) that drive the development of diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer.
In relation to the CCIC, her lab is currently examining how various forms of inhaled cannabis and/or cannabinoids affects lung and immune function. Using pre-clinical models, her team will investigate activation of cellular signaling pathways by exposure to cannabis/cannabinoids, how cannabis exposure effects immune cell numbers and function and whether newer forms of inhaled cannabis products impact lung function. Working with clinicians and other scientists, she is developing an interdisciplinary program for biomedical cannabis research to explore the full potential of cannabis and cannabinoids in human health and disease. For this, she will have a state-of-the-art inhalation facility. This is important, as the most common way to consume cannabis is through inhalation (of smoke or vaporized cannabis/cannabinoids). With this, she will be able to deliver inhaled cannabis and cannabis-derived cannabinoids/novel drugs in a real-world scenario to assess efficacy in disease models and understand the immune-medicated mechanisms involved in the potential therapeutic benefits of cannabis.
View full publication:Human airway branch variation and chronic obstructive pulmonary disease. Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM, Guo J, Han MK, Hansel NN, Hughes EW, Jacobs DR Jr, Kanner RE, Kaufman JD, Kleerup E, Lin CL, Liu K, Lo Cascio CM, Martinez FJ, Nguyen JN, Prince MR, Rennard S, Rich SS, Simon L, Sun Y, Watson KE, Woodruff PG, Baglole CJ, Barr RG; MESA Lung and SPIROMICS investigators. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E974-E981. doi: 10.1073/pnas.1715564115. Epub 2018 Jan 16. PMID: 29339516
Dr. Carolyn Baglole was interviewed about her recent grant entitled “Prognostic and therapeutic utility of human antigen R (HUR) in idiopathic pulmonary fibrosis”. Her project received 2 year funding from Boehringer-Ingleheim’s Innovation in Understanding ILD (BUILD) program. (April 2017)
Read more here: BUILD grant breathes life into lung disease research. Supported by funding from Boehringer Ingelheim (Canada) Ltd, Carolyn Baglole hopes to unravel the mystery of idiopathic pulmonary fibrosis, a fatal lung disease that affects some 15,000 Canadians.
Scientists discover peptide that could reduce the incidence of RSV-related asthma
New research published in the Journal of Leukocyte Biology suggests that a peptide developed to inhibit a key regulator of asthma responses reduces development of inflammation and ‘twitchy’ airways in mice
For Details: Bharat T. Srinivasa, Katherine H. Restori, Jichuan Shan, Louis Cyr, Li Xing, Soojin Lee, Brian J. Ward, and Elizabeth D. Fixman. STAT6 inhibitory peptide given during RSV infection of neonatal mice reduces exacerbated airway responses upon adult reinfection. doi:10.1189/jlb.4A0215-062RR ; http://www.jleukbio.org/content/101/2/519.abstract
New milk allergy research being led at the RI-MUHC. Pediatric allergy and immunology specialists Dr. Bruce Mazer and Dr. Moshe Ben-Shoshan (Montreal Children’s Hospital) started the GET-FACTS (Genetics, Environment and Therapies: Food Allergy Clinical Tolerance Studies) study in 2012.
The program is having good success with helping children with milk allergies build up tolerance to milk protein by introducing the allergen very slowly into the diet. They were interviewed by CTV, La Presse, Radio-Canada, 98,5 fm, the Gazette, CJAD and Le Devoir (September 2016).
Dr. Bruce Mazer explains how the Learning Early about Peanut Allergy (LEAP) trial is changing our approach to peanut allergy. The study (published in NEJM 2015) found that infants (between 4−11 months) who consumed at least 6 grams of peanut per week were significantly less likely to develop an allergy by 5 years of age, compared to infants who avoided peanut entirely.